Korean Medical Research Center for Healthy Aging, Pusan National University, Yangsan, Gyeongsangnam-do 50612, Korea.
Department of Korean Medical Science, School of Korean Medicine, Pusan National University, Yangsan, Gyeongsangnam-do 50612, Korea.
Biomolecules. 2021 Mar 16;11(3):439. doi: 10.3390/biom11030439.
Despite advances in assisted reproductive technology, treatment for deficient endometrial receptivity is a major clinical unmet need. In our previous study, the water extract of Pall. enhanced endometrial receptivity in vitro and in vivo via induction of leukemia inhibitory factor (LIF), an interleukin (IL)-6 family cytokine. In the present study, we found that paeoniflorin, a monoterpene glycoside, is the major active compound of . Paeoniflorin significantly improved the embryo implantation rate in a murine model of mifepristone (RU486)-induced implantation failure. In addition, paeoniflorin increased the adhesion of human trophectoderm-derived JAr cells to endometrial Ishikawa cells through the expression of LIF in vitro. Moreover, using the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database of the human endometrium, we confirmed that LIF signaling is a key regulator for improving human endometrial receptivity. Therefore, these results suggest that paeoniflorin might be a potent drug candidate for the treatment of endometrial implantation failure by enhancing endometrial receptivity.
尽管辅助生殖技术取得了进展，但治疗子宫内膜容受性不足仍是一个主要的临床未满足需求。在我们之前的研究中，白芍水提物通过诱导白细胞介素 6 家族细胞因子白血病抑制因子（LIF），在体外和体内增强了子宫内膜容受性。在本研究中，我们发现芍药苷是白芍的主要活性化合物，芍药苷显著提高了米非司酮（RU486）诱导着床失败的小鼠模型中的胚胎着床率。此外，芍药苷通过体外表达 LIF 增加了人滋养层衍生的 JAr 细胞与子宫内膜 Ishikawa 细胞的黏附。此外，我们利用国立生物技术信息中心（NCBI）的人类子宫内膜基因表达综合数据库（GEO），证实了 LIF 信号通路是改善人类子宫内膜容受性的关键调节剂。因此，这些结果表明，芍药苷可能是通过增强子宫内膜容受性治疗子宫内膜着床失败的有效药物候选物。
